Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
暂无分享,去创建一个
R. Mesa | A. Tefferi | A. Pardanani | C. Li | C. Hanson | C. Finke | T. Lasho | C. Finke | Jocelin Huang | J. Huang | W. Wu | W. Wu | chin-Yang Li
[1] Paola Guglielmelli,et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.
[2] R. Mesa,et al. Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis. , 2007 .
[3] D. Gary Gilliland,et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.
[4] D. Gilliland,et al. Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes , 2007, Stem cells.
[5] R. Mesa,et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia , 2007, Leukemia.
[6] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[7] D. Gilliland,et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.
[8] W. Vainchenker,et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. , 2007, Blood.
[9] Paola Guglielmelli,et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.
[10] D. Carbone,et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. , 2007, Blood.
[11] T. Barbui,et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.
[12] A. Tefferi,et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera , 2007, Leukemia.
[13] A. Tefferi,et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.
[14] A. Tefferi,et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera , 2007, Leukemia.
[15] A. Tefferi,et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder , 2007, Leukemia.
[16] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[17] R. Levine,et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time , 2006, British journal of haematology.
[18] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.
[19] P. Campbell,et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.
[20] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[21] D. Steensma,et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained , 2006, Leukemia.
[22] M. Calasanz,et al. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients , 2006, Leukemia.
[23] P. Campbell,et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.
[24] M. Wadleigh,et al. The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.
[25] P. Campbell,et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.
[26] D. Steensma,et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .
[27] P. Guglielmelli,et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.
[28] David P Steensma,et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.
[29] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[30] R. McClure,et al. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.
[31] B. Woda,et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features , 2006, Leukemia.
[32] R. Levine,et al. The JAK 2 V 617 F activating tyrosine kinase mutation is an infrequent event in both “ atypical ” myeloproliferative disorders and myelodysplastic syndromes , 2005 .